摘要
目的研究人乳腺珠蛋白(hMAM)在乳腺组织中表达的特异性,hMAM的表达与各临床病理特征以及与乳腺癌预后的关系。方法运用免疫组织化学的方法分析142例原发性乳腺癌组织,103例其他肿瘤组织,30例正常乳腺组织,30例乳腺良性肿瘤中的hMAM表达情况,并结合乳腺癌患者的临床病理资料和生存情况进行分析。结果 hMAM只在乳腺组织中表达,在原发性乳腺癌中有70.4%的阳性表达。hMAM的表达与年龄、临床分级分期、肿块大小、腋淋巴结状态、病理类型、PR、HER2状态均无相关性,与ER呈正相关。生存分析显示,hMAM阳性患者预后明显好于hMAM阴性患者,Cox回归示年龄、临床分期、ER、hMAM状态均对乳腺癌的术后生存时间有影响。结论 hMAM具有理想的乳腺组织表达特异性,在原发性乳腺癌组织中有较高的表达率同时具备较高的敏感度和特异性。生存分析显示hMAM可以作为评估原发性乳腺癌患者预后的重要参考指标。
Objective To confirm whether hMAM is a mammary-specific marker, and to investigate the relationship between the hMAM expression and the clinicopathologic characteristics, and to estimate the prognostic value of hMAM. Methods One humdred and Forty-two primary breast cancer patients between 1996 to 2003, 103 various organ tumors,30 normal breast tissues and 30 benign breast tumors were analyzed by immunohistochemical assay. Results hMAM was detected in 70.4% primary breast cancer patients, and its expression was associated with positive expression of ER, but not with age,pathologic type,HER2 status,tumor size, clinicopathologic stage, or PR status. Kaplan-Meier survival analysis explored a significant difference between hMAM-positive and hMAM-negative expression, and the former had a better outcome. COX multivariate analysis revealed that pathologic stage, ER expression, age and hMAM significantly and independently affect overall survival. Conclusion hMAM was highly expressed in breast cancer patients and have an ideal sensitivity and specificity. Survival curve revealed that hMAM was a independent prognostic factor for primary breast cancer patient’s outcome.
出处
《肿瘤防治研究》
CAS
CSCD
北大核心
2010年第6期667-670,共4页
Cancer Research on Prevention and Treatment
关键词
人乳腺珠蛋白
原发性乳腺癌
预后
Human mammaglobin
Primary Breast Cancer
Prognosis
